| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Unknown | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Unknown | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Unknown |
Recent Updates
Recently added Catalysts
Chemomab Therapeutics Ltd.$1.74
-0.09 (-4.92%)
F 19Pipeline Score Richly Valued Biotech · Clinical
Market Cap
14.54 M
EPS
-1.11
P/E Ratio
-
Value Trade
27.79 K
SEC Financials
Q1 2023Dilution Risk
R&D Expenses
6.89 M
Operating CF
-7.19 M
Total Assets
35.01 M
Total Liabilities
7.06 M
Equity
27.95 M
D/E Ratio
12,345
17.44 %
Week
22.42 %
1 Month
25.47 %
3 Month
-18.88 %
6 Month
-97.1 %
5 Year
-99.73 %
All Time
Cash Data
Cash Position
20.77 M
Monthly Burn
2.40 M
Runway
0 mo
Burn Trend
SEC Filing
May 11, 2023
Overview
Volume
176.79 K
52 Week Range
1.35 - 5.77
% held by Insiders
4.53 %
% held by Institutions
4.84 %
Enterprise Value
6.50 M
Total Shares
7.20 M
Short %
1.95 %
Float Shares
6.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Chemomab Therapeutics Ltd.
165Total events
6Upcoming
30Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 6
Event history 159
Jul 8, 2026
Jul 8, 2026
May 30, 2026
◆Poster PresentationnebokitugPresentation
Three poster presentations at EASL 2026 on nebokitug in PSC
primary sclerosing cholangitissource ↗
May 14, 2026
May 4, 2026
◆Oral PresentationnebokitugPresentation
Oral presentation at DDW 2026 on proteomic study of nebokitug in PSC
primary sclerosing cholangitissource ↗
Feb 26, 2026
◆Oral PresentationPresentation
Corporate presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Drug Pipeline Intelligence
F19
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 18%
Micro Cap (rank 748 of 911)
Percentile RankChemomab Therapeutics Ltd. has significant pipeline risk (19/100), with $216M risk-adjusted pipeline value, led by Anti-human CCL24 monoclonal antibody in Healthy (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-human CCL24 monoclonal antibody Monoclonal antibody | Primary Sclerosing Cholangitis | Phase 2 | NCT04595825 | 21% | $146M | ACTIVE NOT_RECRUITING | 68 | AVERAGE | B (62) | Sep 1, 2025 | - | May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nebokitug | primary sclerosing cholangitis | Phase 2 | 2026-02-17 | positive results from five clinical trials | Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
nebokitug | primary sclerosing cholangitis | Phase 2 | 2026-02-17 | positive results from five clinical trials | Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
nebokitug | primary sclerosing cholangitis | Phase 2 | 2026-02-17 | positive results from five clinical trials | Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CMMB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CMMB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CMMB▼ -28.9%on this news
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab Therapeutics and Scipher Medicine have announced a merger to advance nebokitug, an anti-CCL24 antibody, through a Phase 2 trial for rheumatoid arthritis. The merger is supported by a $30 million financing commitment and aims to leverage Scipher's AI platform for patient selection. The combined company will operate under the name Scipher Medicine Corporation and is expected to close in Q4 2026, pending shareholder approvals.
Read more →CMMBChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported its Q1 2026 financial results, highlighting advancements in its nebokitug program for primary sclerosing cholangitis (PSC). New clinical data presented at major medical meetings indicates nebokitug's potential as a disease-modifying treatment, particularly for PSC patients with co-existing inflammatory bowel disease (IBD). The company is actively pursuing strategic partnerships and has a solid cash position to support ongoing operations.
Read more →CMMBChemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics (NASDAQ: CMMB) reported its financial results for the year and fourth quarter ending December 31, 2025, highlighting significant progress in its nebokitug program for primary sclerosing cholangitis (PSC). The company successfully navigated an FDA End-of-Phase 2 meeting, establishing a clear pathway toward a potential Phase 3 clinical trial. Key achievements from the year included positive SPRING trial results, several scientific presentations that underscored nebokitug's therapeutic potential, and ongoing discussions with strategic partners to advance the program. These developments may ultimately lead to nebokitug becoming the first approved therapy for PSC and other fibro-inflammatory conditions.
Read more →CMMBChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dr. Adi Mor and the senior management team will present and engage in one-on-one investor meetings. The company is known for its innovative therapies targeting fibro-inflammatory diseases, particularly its monoclonal antibody nebokitug, which has shown promising results in clinical trials.
Read more →CMMBChemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Chemomab Therapeutics announced the publication of results from its Phase 2 SPRING trial assessing nebokitug in primary sclerosing cholangitis (PSC). The study indicated that nebokitug was safe and well-tolerated for up to 48 weeks, with notable improvements in inflammation and fibrosis biomarkers, especially at the 20 mg/kg dose. These promising results support the initiation of a Phase 3 trial, which aims to further evaluate nebokitug's efficacy in treating PSC, a disease currently without adequate treatment options.
Read more →CMMBChemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025. CEO Adi Mor will present a corporate overview and engage in one-on-one meetings with investors. The company is notably advancing nebokitug, a monoclonal antibody designed to treat fibro-inflammatory diseases, which has shown positive results in clinical trials and received favorable regulatory designations from the FDA and EMA. This summit marks an important opportunity for Chemomab to strengthen investor relations and discuss their innovative therapeutic developments.
Read more →CMMB▼ -10%on this newsshared move
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported positive developments regarding its nebokitug Phase 3 trial for primary sclerosing cholangitis (PSC). The company received favorable feedback from the FDA and EMA, indicating that a single registration trial could suffice for approval. Recent data presented at AASLD 2025 highlighted nebokitug's potential to modify disease progression in PSC patients. Chemomab is also exploring partnerships to support the trial's advancement.
Read more →CMMBChemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab Therapeutics announced that new clinical data from the Phase 2 SPRING trial of nebokitug will be presented at AASLD The Liver Meeting 2025. The data indicates that nebokitug has shown favorable safety and consistent improvements in key biomarkers in patients with primary sclerosing cholangitis (PSC). The company aims to initiate a Phase 3 trial based on these promising results.
Read more →CMMBChemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Chemomab Therapeutics announced that CEO Dr. Adi Mor will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be available via webcast on September 5, 2025. The company is also hosting one-on-one investor meetings during the conference. Chemomab's lead product, nebokitug, has shown positive results in clinical trials and is preparing for a Phase 3 trial in primary sclerosing cholangitis.
Read more →CMMB▼ -6.3%on this news
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics has reported its financial results for Q2 2025, highlighting progress in the Phase 3 program for nebokitug, aimed at treating primary sclerosing cholangitis (PSC). The company is actively seeking strategic partnerships to enhance development resources and has aligned with the FDA on regulatory requirements. Additionally, Chemomab plans to adjust its American Depositary Shares ratio, effective August 26, 2025.
Read more →CMMBChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Chemomab Therapeutics presented positive Phase 2 SPRING trial data for nebokitug in primary sclerosing cholangitis (PSC) at BSG Live'25. The treatment demonstrated a favorable safety profile and significant improvements in biomarkers associated with PSC progression. The findings support the advancement of nebokitug to a Phase 3 trial, aiming to address the unmet need for effective PSC therapies.
Read more →CMMB▼ -7.5%on this news
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
Chemomab Therapeutics has received positive feedback from the FDA regarding its Phase 3 development program for nebokitug, a treatment for primary sclerosing cholangitis (PSC). The FDA agreed on the Chemistry, Manufacturing, and Controls (CMC) strategy and allowed non-clinical toxicology studies to proceed concurrently with the clinical trial. This advancement supports Chemomab's efforts to finalize the trial details and engage with strategic partners.
Read more →CMMBChemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Chemomab Therapeutics has received new patent protections for its drug nebokitug in China and Russia, enhancing its intellectual property portfolio. The drug is positioned to potentially become the first approved treatment for primary sclerosing cholangitis (PSC), following positive results from the Phase 2 SPRING trial. The FDA has also outlined a clear pathway for regulatory approval, which is a significant milestone for the company.
Read more →CMMB▲ +6.6%on this news
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported its financial results for Q1 2025 and highlighted significant milestones for its lead candidate, nebokitug. The company achieved a clear regulatory pathway with the FDA for a Phase 3 trial aimed at treating primary sclerosing cholangitis (PSC). Positive data from the SPRING trial showed that nebokitug improved key biomarkers in patients with moderate/advanced PSC. Chemomab's cash position is robust, extending its runway into the second quarter of 2026, and it is exploring partnership options to advance its clinical program.
Read more →CMMB▼ -6.3%on this news
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
Chemomab Therapeutics has presented promising Phase 2 data for its drug nebokitug in treating primary sclerosing cholangitis (PSC) at DDW 2025. The trial demonstrated that nebokitug is well-tolerated and showed significant improvements in various biomarkers related to disease progression over 48 weeks. This encouraging data has prompted the company to advance nebokitug to a Phase 3 study, reflecting its potential as a first-in-class treatment for PSC, a disease with currently no FDA-approved therapies.
Read more →CMMBChemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab Therapeutics has announced promising clinical data for its treatment, nebokitug, at EASL 2025. The analysis from the Phase 2 SPRING trial indicates significant and dose-dependent improvements in various biomarkers associated with primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. Furthermore, pharmacokinetic data demonstrates effective engagement between nebokitug and its target, CCL24, suggesting a robust clinical potential for the therapy in treating PSC. The data will be presented at the upcoming EASL congress in Amsterdam.
Read more →CMMBChemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Chemomab Therapeutics announced that it will present clinical data on nebokitug (CM-101) for primary sclerosing cholangitis at major upcoming scientific conferences. The company has reported positive results from previous trials and is preparing for a Phase 3 trial based on its Phase 2 SPRING trial outcomes. Nebokitug has received Orphan Drug and Fast Track designations from regulatory authorities.
Read more →CMMBChemomab Announces New Medical and Clinical Appointments
Chemomab Therapeutics has announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer and Jack Lawler as Chief Development Officer. Weiner returns to the company with extensive experience in drug development, while Lawler has been pivotal in the successful Phase 2 SPRING trial for their product nebokitug. The company anticipates a smooth transition as it plans the next steps following the trial's success. However, there are inherent risks in obtaining regulatory approval and market acceptance for nebokitug.
Read more →CMMB▼ -5.2%on this news
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Chemomab Therapeutics announced positive results from the Open Label Extension of the Phase 2 SPRING trial for nebokitug, a treatment for primary sclerosing cholangitis (PSC). After 48 weeks of treatment, patients showed substantial improvements in liver injury and fibrosis biomarkers, as well as lower rates of clinical events compared to historical controls. The positive findings support the planned Phase 3 trial and suggest the potential for nebokitug to be a disease-modifying therapy for PSC, a condition with no current FDA-approved treatments.
Read more →CMMB▼ -10.1%on this news· ran to -23% by day 1
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Chemomab Therapeutics reported its financial results for the year and fourth quarter ending December 31, 2024, alongside a corporate update. The company successfully completed an FDA End-of-Phase 2 meeting, setting a clear pathway for regulatory approval of nebokitug for treating Primary Sclerosing Cholangitis (PSC) without needing liver biopsies or confirmatory studies. Positive results from the Phase 2 SPRING trial have been highlighted, with nebokitug showing a favorable safety profile and efficacy improvements in patients with moderate to advanced disease. The company is preparing to advance towards a pivotal Phase 3 trial in the ongoing pursuit of addressing the unmet needs in PSC.
Read more →CMMBChemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Chemomab Therapeutics has successfully completed its End-of-Phase 2 meeting with the FDA, which aligns the company on a Phase 3 pivotal trial design for nebokitug (CM-101) aimed at treating primary sclerosing cholangitis (PSC). The trial offers regulatory clarity by eliminating the need for liver biopsies and focusing on clinically impactful events related to disease progression. The innovative design could potentially position nebokitug as the first FDA-approved therapy for PSC, addressing a significant unmet medical need. Plans for advancing discussions with strategic partners and preparing for the trial launch are underway.
Read more →CMMBChemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics Ltd. will take part in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The company's CEO and senior management will present the firm's developments and hold one-on-one investor meetings via a virtual format. Chemomab is advancing its lead candidate, CM-101, which targets fibro-inflammatory diseases and has demonstrated positive results in clinical trials. The company anticipates critical milestones in early 2025 concerning FDA pathways for CM-101.
Read more →CMMBChemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics has reported its financial results for the third quarter of 2024, highlighting positive outcomes from its Phase 2 SPRING trial for CM-101 in primary sclerosing cholangitis (PSC). The company plans to meet with the FDA in late 2024 to discuss the design of a Phase 3 trial for CM-101, which is anticipated to begin in 2025. Financially, Chemomab has extended its cash runway to early 2026 following a successful private placement, while discussions with strategic partners are ongoing to expedite the development of CM-101. The promising Phase 2 results have led to heightened interest from potential partners in advancing the drug's clinical program.
Read more →CMMBChemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. will release its third quarter 2024 financial results on November 14, 2024. The company is developing CM-101, a monoclonal antibody for fibrotic diseases, which has shown promising results in past clinical trials. Chemomab anticipates key milestones early in 2025 for its ongoing PSC trial, including FDA feedback and further data. Investors can contact the company for more details after the results are published.
Read more →CMMB▲ +9.2%on this news· ran to +31% by day 3
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting 2024
Chemomab Therapeutics announced that the Phase 2 SPRING trial results of CM-101 for primary sclerosing cholangitis (PSC) will be presented orally at the 2024 AASLD The Liver Meeting. The results indicate improved fibrosis biomarkers in patients. The presentation is scheduled for November 18, 2024, by Professor Christopher Bowlus. Chemomab is anticipating further developments, including FDA feedback for its planned Phase 3 trial in 2025.
Read more →CMMBChemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab Therapeutics Ltd. has announced its participation in two investor conferences in October 2024. The company's senior management will attend the Third Annual ROTH Healthcare Opportunities Conference in New York City on October 9 and CEO Dr. Adi Mor will participate in a fireside chat during the Maxim Healthcare Virtual Summit on October 16. Chemomab is developing CM-101, a monoclonal antibody for fibro-inflammatory diseases, which has shown promise in clinical trials and has received FDA designations. A recording of the chat will be available on their investor relations website after the event.
Read more →CMMB▲ +12.7%on this news· ran to +49% by day 3
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab Therapeutics Ltd. announced that CEO Dr. Adi Mor will present at the H.C. Wainwright 26th Annual Global Investment Conference and HBM Biopharma Summit 2024. The H.C. Wainwright presentation will be available as a prerecorded webcast starting on September 9, 2024, while the HBM presentation will occur live in Zurich on September 23, 2024. Chemomab's CM-101 monoclonal antibody has shown positive results in clinical trials targeting severe fibro-inflammatory diseases.
Read more →CMMBChemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics has announced its financial results for the second quarter of 2024, highlighting positive outcomes from its Phase 2 SPRING trial for CM-101 in patients with primary sclerosing cholangitis. The trial demonstrated safety and significant clinical effects, establishing proof-of-concept for CM-101. The company also completed a successful $10 million PIPE financing, ensuring operations are funded through early 2026. Looking ahead, Chemomab is planning to advance CM-101 into a Phase 3 trial and expects to discuss FDA requirements in upcoming meetings.
Read more →CMMBChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. will report its second quarter 2024 financial results and provide a business update on August 21, 2024. The company focuses on developing innovative therapeutics for fibro-inflammatory diseases, particularly with its monoclonal antibody CM-101. This therapy targets the soluble protein CCL24, showing promise in multiple clinical trials. Investors can discuss the results after the earnings release.
Read more →CMMBChemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab Therapeutics Ltd. has announced the successful closing of a $10 million private placement, involving participation from investors such as HBM Healthcare Investments, OrbiMed, and Sphera Biotech Master Fund LP. This financing extends the company’s cash runway potentially to the beginning of 2026. The firm is well-positioned to achieve key clinical milestones in Q1 2025, backed by positive results from its Phase 2 trials. The private placement included 8,097,167 American Depositary Shares and was facilitated by Oppenheimer & Co. Inc.
Read more →CMMB▲ +6.7%on this newsshared move
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab Therapeutics Ltd. has announced that it has regained compliance with the minimum bid price requirement set by the Nasdaq Stock Market. This compliance was achieved after the company's American Depositary Shares (ADSs) closed at $1.00 or higher for ten consecutive business days. Previously, the company had been notified in November 2023 of non-compliance due to a prolonged period of share prices below the requirement. The company is actively developing CM-101, a therapeutic for fibro-inflammatory diseases, and has reported positive clinical trial outcomes related to this treatment.
Read more →CMMB▼ -16.2%on this newsshared move
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab Therapeutics has announced a $10 million private placement aimed at extending its cash runway through 2026. The investment, which involves participation from both new and existing investors, will primarily fund the development of CM-101 and cover general corporate expenses. Despite the optimistic outlook, the company faces risks related to clinical trial outcomes, regulatory approvals, and market acceptance for its lead product.
Read more →CMMB▼ -16.2%on this newsshared move
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
Chemomab Therapeutics announced positive topline results from the Phase 2 SPRING trial for CM-101, a first-in-class monoclonal antibody targeting primary sclerosing cholangitis (PSC). The trial met both its primary and secondary endpoints, showing significant improvements in liver stiffness and other relevant biomarkers. CM-101 exhibited a favorable safety profile and was well-tolerated by patients. These results provide clinical proof-of-concept and pave the way for plans toward a Phase 3 trial in 2025 following discussions with the FDA.
Read more →CMMB▲ +11.5%on this news
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics announced new publications reinforcing the potential of its CCL24-neutralizing antibody, CM-101, in treating primary sclerosing cholangitis (PSC). Recent research highlights the significant role of CCL24 in PSC progression, supporting CM-101's therapeutic capabilities. The Phase 2 PSC trial's topline data is expected by mid-year 2024, raising hopes for its effectiveness in this condition with no FDA-approved treatments available. The publications emphasize the importance of CCL24 and provide insights for advancements in monitoring disease progression.
Read more →CMMB▼ -11.6%on this news· ran to -22% by day 3
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Chemomab Therapeutics presented new data supporting the clinical potential of its drug CM-101 for treating primary sclerosing cholangitis (PSC) at EASL 2024. Two scientific posters highlighted key findings, including the drug's ability to reduce hepatic stellate cell activation in patients with liver fibrosis, and a machine learning-derived protein signature model that predicts PSC presence and severity. The company is eagerly anticipating topline results from its ongoing Phase 2 trial of CM-101, which is expected midyear 2024. The presentations also emphasized the importance of CCL24 as a therapeutic target in fibrotic liver diseases.
Read more →CMMBChemomab Therapeutics to Participate in Upcoming Scientific Conferences
Chemomab Therapeutics announced its participation in significant upcoming scientific conferences, including the Gordon Research Conference on Chemotactic Cytokines and EASL 2024 in Milan. The company will present research on its CCL24 neutralizing antibody, CM-101, which is in development for fibro-inflammatory diseases, particularly primary sclerosing cholangitis. Presentations will highlight the efficacy and safety of CM-101, and include various translational studies to support its clinical development. Chemomab's ongoing engagements reflect its commitment to addressing unmet medical needs in severe diseases.
Read more →CMMB▲ +11.7%on this news
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics has reported its financial and operational results for the first quarter of 2024, showcasing promising progress in its clinical trial for CM-101, a treatment for primary sclerosing cholangitis (PSC). Notably, the company completed patient enrollment for the Phase 2 trial six months ahead of schedule and expects topline data by mid-2024. Additional peer-reviewed publications have bolstered the understanding of the CCL24 target, further supporting Chemomab's approach. The company also noted improvements in its financials, with a reduction in research and development expenses compared to the previous year, and sufficient liquidity to sustain operations through March 2025.
Read more →CMMB▼ -18.4%on this newsshared move
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Chemomab Therapeutics has been granted a 180-day extension by Nasdaq to comply with the minimum bid price requirement, allowing until November 4, 2024, to meet the $1.00 per share threshold. The company is eligible for this extension based on meeting other listing requirements and has expressed its intention to cure the deficiency. Meanwhile, Chemomab continues to develop its CM-101 therapeutic, which has shown promise in treating severe fibro-inflammatory diseases in clinical trials, with topline data expected mid-2024. However, the stock's current non-compliance poses risks to its market position.
Read more →CMMBChemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Chemomab Therapeutics Ltd. has announced that CEO Dr. Adi Mor will deliver a presentation at the Aegis Virtual Conference on May 7, 2024. The conference will feature a live webcast of the presentation, highlighting Chemomab's innovative therapeutics for fibro-inflammatory diseases. Chemomab has reported positive outcomes from clinical trials involving its lead product, CM-101, which targets CCL24. With an open U.S. IND, the company is advancing its CM-101 program for the treatment of systemic sclerosis.
Read more →CMMBChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. will report its first quarter 2024 financial results and provide a business update on May 9, 2024. The company focuses on developing therapeutics for fibro-inflammatory diseases and has made significant advancements with its CM-101 monoclonal antibody. Positive results from clinical trials indicate CM-101's safety and potential effectiveness in treating severe conditions, including liver fibrosis and lung injury. An update on ongoing trials is anticipated to provide further insights into the company's progress.
Read more →CMMB▲ +18.6%on this news
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Chemomab Therapeutics has published a study providing further evidence that CCL24 plays a significant role in the severity of systemic sclerosis (SSc). Involving over 200 patients, the longitudinal study found that elevated serum CCL24 levels are associated with critical clinical variables including skin fibrosis and interstitial lung disease. Additionally, a higher baseline CCL24 level is predictive of increased mortality among SSc patients. This study underlines the potential of Chemomab's CCL24-neutralizing antibody, CM-101, as a promising therapeutic option for this condition, which currently lacks effective treatments.
Read more →CMMBChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Chemomab Therapeutics Ltd. is set to host a virtual Key Opinion Leader event on April 10, 2024, focusing on primary sclerosing cholangitis (PSC). The event will feature discussions from notable experts, including Dr. Christopher Bowlus and Ricky Safer, on PSC management and clinical developments. Additionally, the CEO and CMO will provide insights regarding the CM-101 Phase 2 trial, which targets PSC and shows potential efficacy based on previous trials. A recorded version of the webinar will be available post-event on the company's website.
Read more →CMMB▼ -5.6%on this news
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab Therapeutics has been awarded a new patent by the European Patent Office for its drug CM-101, which is currently in Phase 2 clinical development for the treatment of primary sclerosing cholangitis (PSC). This patent provides additional intellectual property protection, which complements existing patents in various global markets. CM-101 is unique due to its dual mechanism of action that targets fibrosis and inflammation, and it has shown positive results in previous clinical trials. A topline data readout from the ongoing Phase 2 trial is anticipated in mid-2024, potentially affirming its therapeutic efficacy.
Read more →CMMBChemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biol
Read more →CMMBChemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients Announced first patient enro
Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients Announced first patient enrolled in two Phase IIa studies of CM-101 Completed merger
Read more →CMMBFIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT THIS FIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT (the " Amendment "), is made effective as of the 31 th day of March, 2021 (the " Amendment Date "
ASSET PURCHASE AND ASSIGNMENT THIS FIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT (the "Amendment"), is made effective as of the 31th day of March, 2021 (the "Amendment Date") by and between Anchiano Therapeutics, Inc., a company organized under the laws of Delawa
Read more →CMMBAnchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive appro
Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which wi
Read more →CMMBAnchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases
Anchiano Therapeutics and Chemomab Announce Definitive Merger Agreement lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need financing to be used to fund clinical trial
Read more →CMMBAnchiano Appoints Steve DiPalma as Chief Financial Officer
Anchiano Appoints Steve DiPalma as Chief CAMBRIDGE, Mass., May 5, 2020 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the "Company") today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchian
Read more →CMMBTARGETING GENETICALLY - DEFINED CANCERS Corporate Presentation February 2020
TARGETING GENETICALLY - DEFINED CANCERS Corporate Presentation February 2020 Safe Harbor Statement This presentation contains forward - looking statements within the meaning of U.S. federal securities laws and Israeli securities laws that involve risks and uncertainties. These f
Read more →CMMBAnchiano Therapeutics Ltd. Consolidated Interim Financial Statements
Anchiano Therapeutics Ltd. Consolidated Interim Financial Statements Anchiano Therapeutics Ltd. Consolidated Interim Financial Statements as of September 30, 2019 (Unaudited) Page Condensed Consolidated Interim Financial Statements : Condensed Consolidated Interim Sta
Read more →CMMBAnchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program Mass., November 15, 2019 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano" or the "Com
Read more →CMMBAnchiano Therapeutics Chairman Stephen Hoffmann Steps Down from Board
Anchiano Therapeutics Chairman Stephen Hoffmann Steps Down from Board CAMBRIDGE, Mass., October 24, 2019 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano" or the "Company"), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted t
Read more →CMMBAnchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/ -catenin Inhibitor Programs Anchiano will make an upfront payment in exchange for th
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/ -catenin Inhibitor Programs Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Dru
Read more →CMMBAnchiano Therapeutics Reports Second Quarter 2019 Financial Results
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results CAMBRIDGE, Mass., Aug. 5, 2019 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer,
Read more →CMMBAnchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange
Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange Mass., June 18, 2019 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer,
Read more →CMMBANCHIANO THERAPEUTICS LTD. (the Company, our or us ) Notice of Annual General Meeting of Shareholders of the Company Notice is hereby given that the 2019 Annual General Meeting of Shareholders (the Annual Meeting ) of th
ANCHIANO THERAPEUTICS LTD. (the "Company," Notice of Annual General Meeting of Shareholders of the Company Notice is hereby given that the 2019 Annual General Meeting of Shareholders (the "Annual Meeting") of the Company will be held on Tuesday, July 2, 2019 at 4:00 p.m. (Isr
Read more →CMMBAnchiano Therapeutics Reports First Quarter 2019 Financial Results - Closed $30.5 million U.S. Initial Public Offering in February 2019
Anchiano Therapeutics Reports First Quarter 2019 Financial Results Closed $30.5 million U.S. Initial Public Offering in February CAMBRIDGE, Mass., May 22, 2019 - Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused
Read more →CMMBAnchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange CAMBRIDGE, Mass., March 14, 2019 - Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) ("Anchiano") today announced an update with respect to its intention to vol
Read more →CMMBAnchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results - Successfully Completed $30.5 million U.S. Initial Public Offering in February 2019 - - Interim Analysis of the Cod
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results - Successfully Completed $30.5 million U.S. Initial Public Offering in February 2019 - - Interim Analysis of the Codex Clinical Trial Expected in Fourth Quarter 2019 - CAMBRIDGE, Mass., March
Read more →CMMBAnchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public CAMBRIDGE, Mass., Feb. 14, 2019 - Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) ("Anchiano") today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Sha
Read more →CMMBAnchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public CAMBRIDGE, Mass., Feb. 12, 2019 - Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) ("Anchiano") today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Sha
Read more →Competitive Position
How CMMB ranks across every disease it competes inCompetitive Position is a premium feature
See how CMMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial